Phase II Study of Pemigatinib and Durvalumab for Advanced Intrahepatic Cholangiocarcinoma with FGFR-2 Fusion or Rearrangement | Clinical Trial

Phase II Study of Pemigatinib and Durvalumab for Advanced Intrahepatic Cholangiocarcinoma with FGFR-2 Fusion or Rearrangement | Clinical Trial | Right2Hope